Efficacy of cetuximab and mutant selective EGFR inhibitor WZ4002 in EGFR T790M and non-T790M models of erlotinib resistant non-small cell lung cancer

被引：1
|
作者：
Tricker, Erin M. [1 ]
Xu, Chunxiao [1 ]
Wong, Kwok-Kin [1 ]
Janne, Pasi A. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2595
引用
收藏
页数：2
相关论文
共 50 条
  • [41] AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
    Zhao, Ren
    Zhou, Shun
    Xia, Bing
    Zhang, Cui-ying
    Hai, Ping
    Zhe, Hong
    Wang, Yan-yang
    BMC CANCER, 2016, 16
  • [42] Impact of bevacizumab in combination with erlotinib on EGFR-mutatant non-small cell lung cancer xenograft models with T790M mutation or MET amplification
    Furugaki, K.
    Fukumura, J.
    Iwai, T.
    Yorozu, K.
    Yanagisawa, M.
    Moriya, Y.
    Kurasawa, M.
    Yamamoto, K.
    Suda, K.
    Mizuuchi, H.
    Mitsudomi, T.
    Harada, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S611 - S612
  • [43] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [44] Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification
    Furugaki, Koh
    Fukumura, Junko
    Iwai, Toshiki
    Yorozu, Keigo
    Kurasawa, Mitsue
    Yanagisawa, Mieko
    Moriya, Yoichiro
    Yamamoto, Kaname
    Suda, Kenichi
    Mizuuchi, Hiroshi
    Mitsudomi, Tetsuya
    Harada, Naoki
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (04) : 1024 - 1032
  • [45] HS-10182, an EGFR Tyrosine Kinase Inhibitor, Increases Radiation Sensitivity in Non-Small Cell Lung Cancer With EGFR T790M Mutation
    Wang, Y.
    Chen, Y.
    Liu, N.
    Zhao, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E433 - E433
  • [46] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [47] Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
    Li, Yanxia
    Song, Zhendong
    Jin, Yue
    Tang, Zeyao
    Kang, Jian
    Ma, Xiaodong
    MOLECULES, 2016, 21 (11)
  • [48] EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
    Park, Sehhoon
    Ku, Bo Mi
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Lee, Se-Hoon
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1288 - 1290
  • [49] Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer
    Hata, Akito
    Katakami, Nobuyuki
    Nanjo, Shigeki
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Yoshida, Hiroshi
    Zama, Kota
    Imai, Yukihiro
    Hirata, Yukio
    LUNG CANCER, 2017, 111 : 182 - 189
  • [50] TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models
    Miyadera, K.
    Kato, M.
    Takahashi, I.
    Ito, K.
    Aoyagi, Y.
    Fukasawa, K.
    Sagara, T.
    Yonekura, K.
    Iwasawa, Y.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 44 - 44
12345